A clinical-stage biopharmaceutical company focused on developing oncological therapies to improve patient outcomes.

Carrick Therapeutics

Carrick Therapeutics is pioneering a portfolio of unique, first in class, cancer treatments that target driver mechanisms of the most aggressive forms of cancer, and which will be tailored to an individual patient’s tumour.
Targeting the molecular pathways that drive the most aggressive and resistant forms of cancer will transform the way that cancer is treated and have a major impact on the lives of cancer patients. By linking a network of clinicians and scientists in internationally leading research institutes and hospitals, Carrick will streamline the introduction of these ground-breaking cancer therapies into the clinic, thus serving cancer patients around the world.

Woodford Investment Management

Lightstone Ventures

Cambridge Innovation Capital

Evotec

University of Cambridge Enterprise

ARCH Venture Partners

Google Ventures

Pfizer

Revelation Partners

Rosetta Capital

Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer

https://lnkd.in/eTajEtpM

Delighted to announce a First Patient Dosed in our Phase 2b Clinical Trial of Samuraciclib in Combination with Fulvestrant in Patients with Advanced HR+, HER2- Breast Cancer. 

https://lnkd.in/e8deVH6g

Great interview on Oncology Tube with our CMO Stuart McIntosh talking about our ongoing Phase 2 study SUMIT-ELA, combining samuraciclib and elacestrant in patients with CDK4/6i resistant HR+,HER2- metastatic breast cancer in collaboration with Menarini. 

https://lnkd.in/ezt5ZqWW

Delighted to announce US FDA clearance of our IND for CT7439, a First In Class Inhibitor of CDK12/13. Carrick's second therapeutic candidate which further strengthens our oncology pipeline.
https://lnkd.in/e7WuT_9v

COM:CARRICKTHERAPEUTICS

Carrick Therapeutics

Analysis Not Available